CNS effects of a CCR5 inhibitor in HIV-infected subjects: a pharmacokinetic and cerebral metabolite study | Zendy

Lucy Garvey | Zendy; Mark Nelson | Zendy; Ngaire Latch | Zendy; O. W. Erlwein | Zendy; Joanna Allsop | Zendy; Alexis Mitchell | Zendy; Steve Kaye | Zendy; Victoria Watson | Zendy; D.J. Back | Zendy; Simon D. TaylorRobinson | Zendy; Alan Winston | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

CNS effects of a CCR5 inhibitor in HIV-infected subjects: a pharmacokinetic and cerebral metabolite study

Author(s) -

Lucy Garvey,

Mark Nelson,

Ngaire Latch,

O. W. Erlwein,

Joanna Allsop,

Alexis Mitchell,

Steve Kaye,

Victoria Watson,

D.J. Back,

Simon D. TaylorRobinson,

Alan Winston

Publication year - 2011

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkr427

Subject(s) - maraviroc , lopinavir , ritonavir , metabolite , ccr5 receptor antagonist , pharmacokinetics , medicine , emtricitabine , pharmacology , chemistry , viral load , immunology , human immunodeficiency virus (hiv) , antiretroviral therapy , chemokine , receptor , chemokine receptor

We conducted a pharmacokinetic and in vivo cerebral (1)H magnetic resonance spectroscopy ((1)H-MRS) study to assess CSF exposure and cerebral metabolite ratios (CMRs) following maraviroc intensification.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research